NCT06262529

Brief Summary

Affecting more than 150,000 patients in France, stroke is a major public health issue and a leading cause of disability worldwide. In western countries, 80-85% of strokes are of ischemic subtype. This study will focus on young adults, aged 18-45, with a diagnosis of ischemic stroke. Studies assessing post-stroke cognition in young patients reported an alarming prevalence of cognitive impairment, affecting about 60% of stroke survivors between 4 and 12 months after the acute event. However, longitudinal data on neurocognitive trajectories (i.e., the evolution of cognitive impairment over time) in young patients with ischemic stroke are lacking. Collecting such data requires an exhaustive neuropsychological assessment and several functional evaluations, at different times, for the same patient. Repeated neurocognitive study of young patients with ischemic stroke will enable: a description of the prevalence of impaired global cognitive efficiency, an analysis of the specific neurocognitive domains affected, and the tracing of trajectories of recovery from cognitive impairment over time, in terms of global cognitive efficiency and as a function of specific neurocognitive domains (memory, executive, attentional, social cognition, instrumental functions, fatigability, etc.). Up to date, the clinic-radiological predictors and associated factors of neurocognitive impairment after ischemic stroke in young patients have not been studied. Ischemic stroke causes acute brain lesions of the gray matter (GM) and white matter (WM). Numerous studies suggest that cognitive health may be more closely linked to the integrity of WM than to GM. Magnetic resonance imaging (MRI), and in particular diffusion tensor imaging (DTI) sequences, analyze WM bundles. By using fiber tracking algorithms image analysis enable the WM fiber bundle reconstruction and allow quantifying the volume of lesions (pre-existing and ischemic stroke-induced) in the WM tract. The aim of this study is to study whether the extension of pre-existing and acute white matter lesions is associated with poorer cognitive recovery after ischemic stroke, both in terms of global cognitive performance and impairment in specific neurocognitive domains.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
16

participants targeted

Target at below P25 for not_applicable

Timeline
13mo left

Started Feb 2024

Longer than P75 for not_applicable

Geographic Reach
1 country

2 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress69%
Feb 2024May 2027

First Submitted

Initial submission to the registry

February 8, 2024

Completed
Same day until next milestone

Study Start

First participant enrolled

February 8, 2024

Completed
8 days until next milestone

First Posted

Study publicly available on registry

February 16, 2024

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 9, 2025

Completed
2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

May 9, 2027

Expected
Last Updated

March 20, 2025

Status Verified

March 1, 2025

Enrollment Period

1.2 years

First QC Date

February 8, 2024

Last Update Submit

March 18, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • evolution of neurocognitive disorders (trajectories of global cognitive efficiency) over 1 year after stroke

    Montréal cognitive assessment (MOCA - score 0 to 30)

    Between 3 months and 12 months

Study Arms (1)

Acute ischemic stroke

EXPERIMENTAL
Other: Cerebral MRI

Interventions

Cerebral MRI at 72h / 3 months / 12 months

Acute ischemic stroke

Eligibility Criteria

Age18 Years - 45 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Age: 18 to 45 years.
  • Pathology: ischemic stroke diagnosed with brain MRI as per standard clinical practice, with or without occlusion of proximal artery, anterior or posterior circulation.
  • Ability to understand and complete study tests and questionnaires: fluent French speaker and reader.
  • All patients must be affiliated to a social security scheme.
  • Signature of informed consent form.

You may not qualify if:

  • Pre-existing cognitive impairment (defined as CQI \<78 or clinical dementia).
  • Severe functional dependence prior to stroke (defined as Modified Rankin Scale MRS = score 5).
  • Any neurological or psychiatric comorbidity.
  • Sensory disorders: visual impairment, blindness, deafness.
  • Severe acquired phasic disorders: on the expressive oral side, in the presence of an inability to express oneself, which interferes with the collection of responses to neuropsychological tests; and on the receptive oral side, in the presence of an inability to understand the instructions of neuropsychological tests. Phasic functioning is systematically assessed during hospitalization by means of the NIHSS (score ≤ 2 on the "Language" sub-test), and will be rechecked clinically and psychometrically during neuropsychological assessments using the Language Screening Test (LAST) for both expression and oral comprehension. - Severe motor disorders: inability to mobilize the dominant upper limb for written neuropsychological tests.
  • Contraindication to MRI.
  • Pregnant women.
  • HIV-positive patients: interaction of infectious pathology on cognitive functioning. Declarative, no HIV tests will be performed.
  • Withdrawal of informed consent.
  • Consumption of alcohol and/or narcotics on the day of neuropsychological assessments.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

cannes Hospital

Cannes, 06600, France

NOT YET RECRUITING

Nice University Hospital

Nice, 06000, France

RECRUITING

MeSH Terms

Conditions

Ischemic Stroke

Condition Hierarchy (Ancestors)

StrokeCerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesVascular DiseasesCardiovascular Diseases

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
OTHER
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 8, 2024

First Posted

February 16, 2024

Study Start

February 8, 2024

Primary Completion

May 9, 2025

Study Completion (Estimated)

May 9, 2027

Last Updated

March 20, 2025

Record last verified: 2025-03

Data Sharing

IPD Sharing
Will not share

Locations